109 results on '"Rui, Fajuan"'
Search Results
2. Machine Learning–Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis
3. Research Progress in Epidemiology and Risk Factors of Primary Liver Cancer
4. Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study
5. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
6. SAT-388 Comprehensive analysis of CHB concurrent with NAFLD: a proteomics report based on clinical liver samples
7. FRI-022 N-terminal type III collagen propeptide, golgi protein 73 and their combination accurately assess siginificant and advanced fibrosis in chronic hepatitis B patients
8. WED-244 The diminished diagnostic accuracy of existing non-invasive tools for significant fibrosis in MASLD patients concurrent with CHB
9. FRI-404 To establish the threshold for transient elastography indicating advanced fibrosis in patients with chronic hepatitis B and hepatic steatosis
10. TOP-307 The interplay between alcohol consumption and cardiometabolic risk factors in patients with MASLD and MetALD
11. Current research insights into the role of CTLA‐4 in hepatitis B virus (HBV) infection
12. Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
13. Spleen stiffness measurement as a non-invasive assessment in patients with portal hypertension
14. Different minimal alcohol consumption in male and female individuals with metabolic dysfunction‐associated fatty liver disease
15. Superior diagnostic efficacy of Agile 3+ score for diagnosing advanced fibrosis in patients with chronic hepatitis B and concurrent metabolic dysfunction-associated steatotic liver disease.
16. Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management
17. Authors’ reply to: Concerns Regarding “Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study”
18. The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in diabetes patients
19. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
20. Diabetes mellitus (DM) is the strongest risk factor of significant inflammation or fibrosis in chronic hepatitis B (CHB) combined with non-alcoholic fatty liver disease (NAFLD)
21. Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)
22. A diagnostic non-invasive model for liver advanced fibrosis and cirrhosis in chronic hepatitis B (CHB) concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)
23. Comparison of patients with hepatitis B virus‐associated hepatocellular carcinoma: Data from two hospitals from Turkey and China.
24. ADAR1 Inhibits HBV DNA Replication via Regulating miR-122-5p in Palmitic Acid Treated HepG2.2.15 Cells
25. ADAR1 Inhibits HBV DNA Replication via Regulating miR-122-5p in Palmitic Acid Treated HepG2.2.15 Cells
26. Meta‐analysis: global prevalence, trend and forecasting of non‐alcoholic fatty liver disease in children and adolescents, 2000–2021
27. Sa1654 ESTABLISHING AND VALIDATING A HEPATIC INFLAMMATION DIAGNOSTIC MODEL FOR CHRONIC HEPATITIS B PATIENTS WITH CONCURRENT HEPATIC STEATOSIS BASED ON MACHINE LEARNING
28. Sa1653 PERFORMANCE OF A NOVEL MODEL FOR DIAGNOSING ADVANCED FIBROSIS AND CIRRHOSIS IN CHRONIC HEPATITIS B PATIENTS WITH HEPATIC STEATOSIS IN VARIOUS GROUPS
29. Sa1652 PRO-C3, GP73 AND THEIR COMBINATION ACCURATELY ASSESS SIGNIFICANT AND ADVANCED FIBROSIS IN CHRONIC HEPATITIS B PATIENTS
30. Sa1635 TO DETERMINE THE TRANSIENT ELASTOGRAPHY CUT-OFF FOR ADVANCED FIBROSIS IN CHRONIC HEPATITIS B PATIENTS WITH CONCUEERNT HEPATIC STEATOSIS
31. Sa1634 THE DIAGNOSTIC MODELS BASED ON MACHINE LEARNING FOR IDENTIFYING ADVANCED FIBROSIS AND CIRRHOSIS IN CHRONIC HEPATITIS B PATIENTS WITH CONCUEERNT HEPATIC STEATOSIS
32. 1058 THE REDUCED ACCURACY OF NON-INVASIVE TESTS FOR SIGNIFICANT FIBROSIS IN CHB PATIENTS WITH MASLD
33. Establishment and Evaluation of a Prediction Model of BLR for Severity in Coronavirus Disease 2019
34. A K-nearest Neighbor Model to Predict Early Recurrence of Hepatocellular Carcinoma After Resection
35. Increased Risk of Liver-Related Outcomes in Chronic Hepatitis B Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis
36. Derivation and validation of prognostic models for predicting survival outcomes in Acute‐on‐chronic liver failure patients
37. NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea
38. WED-165 - Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
39. SAT-510 - Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)
40. SAT-463 - A diagnostic non-invasive model for liver advanced fibrosis and cirrhosis in chronic hepatitis B (CHB) concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)
41. THU-471 - Diabetes mellitus (DM) is the strongest risk factor of significant inflammation or fibrosis in chronic hepatitis B (CHB) combined with non-alcoholic fatty liver disease (NAFLD)
42. Current directions, conceptions and viewpoints on 2019‑nCoV (Review)
43. Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes
44. Mo1492 PREVALENCE OF NON-LIVER COMORBIDITIES, MODETATE/SEVERE STEATOSIS, NASH AND LIVER FIBROSIS IN ASIAN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): A SYSTEMIC REVIEW AND META-ANALYSIS OF 128 STUDIES
45. Mo1515 DEVELOPMENT AND REGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OVERALL AND IN SELECTED PATIENT COHORTS: A META-ANALYSIS OF 32 LONGITUDINAL STUDIES AND 179,398 ASIAN PATIENTS
46. Mo1485 A META-ANALYSIS OF MORTALITY AND NON-LIVER COMORBIDITY OUTCOMES IN ASIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) - POOL ESTIMATES FROM 29 STUDIES AND 725,573 PATIENTS
47. Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes.
48. The Reduced Accuracy of Non-invasive Tests for Significant Fibrosis in Chronic Hepatitis B Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.
49. A Novel Algorithm for Streamlining Diagnosis of Advanced Liver Fibrosis in CHB Patients with Concurrent Hepatic Steatosis.
50. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.